ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03664232
Recruitment Status : Recruiting
First Posted : September 10, 2018
Last Update Posted : February 11, 2019
Sponsor:
Information provided by (Responsible Party):
Janssen Research & Development, LLC

Brief Summary:
The purpose of this study is to evaluate the efficacy of JNJ-42165279 compared with placebo in the improvement of symptoms of Autism Spectrum Disorder (ASD) during 12 weeks of treatment using the Autism Behavior Inventory (ABI).

Condition or disease Intervention/treatment Phase
Autism Spectrum Disorder Drug: JNJ-42165279 Drug: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Subjects With Autism Spectrum Disorder
Actual Study Start Date : November 7, 2018
Estimated Primary Completion Date : February 17, 2021
Estimated Study Completion Date : March 3, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: JNJ-42165279
Participants will self-administer 25 milligram (mg) JNJ-42165279 tablets orally once-daily for 12 weeks.
Drug: JNJ-42165279
Participants will receive 25 mg JNJ-42165279 orally once-daily for 12 weeks.

Placebo Comparator: Placebo
Participants will self-administer matching placebo tablets orally once-daily for 12 weeks.
Drug: Placebo
Participants will receive a matching placebo orally once-daily for 12 weeks.




Primary Outcome Measures :
  1. Change from Baseline in the Autism Behavior Inventory (ABI) Core Domain Score to Day 85 [ Time Frame: Baseline up to Day 85 ]
    Change from baseline in the ABI core domain score will be reported. ABI is a 62-item questionnaire completed on a web/mobile application. It is part of the Janssen Autism Knowledge Engine (JAKE), a research tool that tracks outcomes in Autism Spectrum Disorder (ASD). Each ABI item is answered on 1 of 2 possible dimensions, quality (how well a person carries out a particular behavior) or frequency (how often a particular behavior occurs). Each item is rated on a scale of 0-3 (never to very often [frequency] or not at all to without help [quality]). The ABI Core Domain Score is calculated as the sum of the scores in the Social Communication Domain and the Repetitive/Restrictive Behavior Domain divided by the total number of items in these 2 domains.

  2. Change from Baseline in ABI Social Communication Domain Score to Day 85 [ Time Frame: Baseline up to Day 85 ]
    Change from baseline in the ABI social communication domain score will be reported. Each item is rated on a scale of 0-3 (never to very often [frequency] or not at all to without help [quality]). The ABI social communication domain score is calculated as the sum of the scores in the social communication domain divided by the total number of items in this domain.

  3. Change from Baseline in ABI Repetitive/Restrictive Behavior (RRB) Domain Score to Day 85 [ Time Frame: Baseline up to Day 85 ]
    Change from baseline in the ABI RRB domain score will be reported. Each item is rated on a scale of 0-3 (never to very often). The ABI RRB domain score is calculated as the sum of the scores in the RRB domain divided by the total number of items in this domain.


Secondary Outcome Measures :
  1. Change from Baseline in the ABI Mood and Anxiety Domain Score to Day 85 [ Time Frame: Baseline up to Day 85 ]
    Change from baseline in the ABI mood and anxiety domain score will be reported. The ABI mood and anxiety domain score is calculated as the sum of the scores in the mood and anxiety domain divided by the total number of items in this domain. Each item is rated on a scale of 0-3 (never to very often).

  2. Change from Baseline in the ABI Challenging Behavior Domain Score [ Time Frame: Baseline up to Day 85 ]
    Change from baseline in the ABI challenging behavior domain score will be reported. The ABI challenging behavior domain score is calculated as the sum of the scores in the challenging behavior domain divided by the total number of items in this domain. Each item is rated on a scale of 0-3 (never to very often).

  3. Change from Baseline in the ABI Self-Regulation Domain Score [ Time Frame: Baseline up to Day 85 ]
    Change from baseline in the ABI self-regulation domain score will be reported. The ABI self-regulation domain score is calculated as the sum of the scores in the self-regulation domain divided by the total number of items in this domain. Each item is rated on a scale of 0-3 (never to very often).

  4. Change from Baseline in the Aberrant Behavior Checklist (ABC) Subscales [ Time Frame: Baseline up to Day 85 ]
    Change from baseline in the ABC subscales will be reported. The ABC is a 58-item behavior rating scale used to measure behavior problems across 5 subscales: Irritability, Lethargy (Social Withdrawal), Stereotypy, Hyperactivity, Inappropriate Speech. Items are rated on a 4-point scale (ranging from 0 [not at all a problem] to 3 [the problem is severe in degree]).

  5. Change from Baseline in the Autism Behavior Inventory-Short Form (ABI-S) Scale Domains [ Time Frame: Baseline up to Day 85 ]
    Change from baseline in the ABI-S scale domains will be reported. ABI-S is the shorter version of the ABI. It consists of 24 items across 5 areas, social communication, RRB, mood and anxiety, challenging behavior, and self-regulation. Each ABI-S domain score is calculated as the sum of the scores in the ABI-S domain divided by the total number of items in this domain. Each item is rated on a scale of 0-3 (never to very often [frequency] or not at all to without help [quality]).

  6. Change from Baseline in the Autism Behavior Inventory-Clinician Interview (ABI-C) Domains [ Time Frame: Baseline up to Day 85 ]
    Change from baseline in the ABI-C domains will be reported. The ABI-C is designed to capture the behaviors of a person with ASD that have occurred over the past week. There are 14 items across each of the 5 domains (social communication, restrictive behaviors, mood and anxiety, self regulation and challenging behavior). The clinician rates the severity of behaviors and level of impairment on a scale of 1 (none) to 7 (very severe).

  7. Change from Baseline in the Clinical Global Impression-Severity (CGI-S) Scale Score [ Time Frame: Baseline up to Day 85 ]
    Change from baseline in the CGI-S scale score will be reported. The CGI-S rating scale is a global assessment that measures the clinician's impression of the severity of illness of the participant. A rating scale of 1-7 is used, with 1="normal, not at all ill" and 7="among the most extremely ill".

  8. Change from Baseline in the Repetitive Behavior Scale - Revised (RBS-R) Scale Score [ Time Frame: Baseline up to Day 85 ]
    Change from baseline in the RBS-R scale score will be reported. The RBS-R is a 43-item rating scale to indicate occurrence of repetitive behaviors and degree to which a behavior is a problem on a range between 0 to 3, where 0 = behavior does not occur and 3 = behavior occurs and is a severe problem.

  9. Change from Baseline in the Zarit Burden Interview (ZBI) Scale Score [ Time Frame: Baseline up to Day 85 ]
    Change from baseline in the ZBI scale score will be reported. The ZBI short version scale consists of 22 items designed to assess the psychological burden experienced by a caregiver. Responses range from 0-4, where 0 = never and 4 = nearly always.

  10. Change from Baseline in the Child Adolescent Symptom Inventory - Anxiety (CASI-Anx) Scale Score [ Time Frame: Baseline up to Day 85 ]
    Change from baseline in the CASI-Anx scale score will be reported. CASI-Anx is a 21-point anxiety subscale of the full CASI. Responses will range from 0 to 3, where 0 = never and 3 = very often.

  11. Change from Baseline in the Social Responsiveness Scale 2 (SRS-2) Score [ Time Frame: Baseline up to Day 85 ]
    Change from baseline in the SRS-2 scale score will be reported. The SRS-2 is a 65-item scale that measures social impairment and includes 5 subscales. Responses range from 1 to 4, where 1 = Not true and 4 = almost always true.

  12. Change from Baseline in the Caregiver Global Impression of Severity (Caregiver GI-S) [ Time Frame: Baseline up to Day 85 ]
    Change from baseline in the Caregiver GI-S scale score will be reported. The Caregiver GI-S is a single-item instrument that asks caregivers to rate their overall impression of the severity of their child's ASD symptoms. Responses range from 1 to 7, where 1 = None and 7 = Severe.

  13. Caregiver Assessment of Treatment Score [ Time Frame: Day 85 ]
    The Caregiver Assessment of Treatment is a 3-item questionnaire. Caregivers rate their global impression of improvement in their child's autism, whether there was improvement in specific symptoms, and their interest in having their child continue the study medication. One item uses a scale of 1 (very much improved) to 7 (very much worse), another item includes a Yes/No checklist, and another item uses a scale of 1 (not at all interested) to 5 (extremely interested).

  14. Self Global Impression of Improvement (Self GI-I) Score [ Time Frame: Day 85 ]
    The participant will be asked to give his/her impression of overall improvement in ASD symptoms using a single-item instrument, the Self GI-I. Responses will range from 1 to 7, where 1 = Very much better and 7 = Very much worse.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   13 Years to 30 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of Autism Spectrum Disorder (ASD) according to Diagnostic and Statistical Manual of Mental Disorders - 5th Edition (DSM-5) criteria and made or confirmed using the Autism Diagnostic Observation Schedule, 2nd edition (ADOS-2) (minimum score of 8 [autism spectrum])
  • Otherwise healthy for their age group or medically stable with or without medication on the basis of physical examination, medical history, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory tests
  • Have a composite score on Kaufman Brief Intelligence Test, Second Edition (KBIT-2) of at least 60
  • Must live with a parent or primary caregiver or, if not, during each week he/she must either (A) spend at least 3 hours a day for at least 4 days or, (B) spend the weekend with a parent or primary caregiver
  • Any pharmacologic, diet, or behavioral intervention for ASD must have begun at least 1 month prior to the baseline visit and continue unchanged through the treatment period, or have ended at least 1 month prior to the baseline visit
  • Must be able to swallow the study medication whole and self-administer medication if living independently or have a parent or caregiver be able to administer medication
  • Must agree to abide by the birth control requirements during the study and for 3 months after the last dose

Exclusion Criteria:

  • Current or recent history of clinically significant suicidal ideation within the past 6 months, or a history of suicidal behavior within the past year
  • Use of a drug with moderate/strong cytochrome P450 (CYP)3A4 inhibiting or inducing properties at, or prior to, screening that is not discontinued at least within 1 month prior to Day 1
  • History of drug or alcohol use disorder according to DSM-5 criteria within 6 months before screening or positive test result(s) for alcohol or drugs of abuse (except if related to current treatment)
  • Currently taking or has taken within the past month recreational or medically prescribed cannabis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03664232


Contacts
Contact: Study Contact 844-434-4210 JNJ.CT@sylogent.com

Locations
United States, Arizona
Southwest Autism Research and Resource Center Recruiting
Phoenix, Arizona, United States, 85006
United States, New York
Nathan Kline Institute Recruiting
Orangeburg, New York, United States, 10962
United States, Washington
Seattle Children's Hospital Not yet recruiting
Seattle, Washington, United States, 98105
Sponsors and Collaborators
Janssen Research & Development, LLC
Investigators
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC

Additional Information:
Responsible Party: Janssen Research & Development, LLC
ClinicalTrials.gov Identifier: NCT03664232     History of Changes
Other Study ID Numbers: CR108275
42165279AUT2001 ( Other Identifier: Janssen Research & Development, LLC )
First Posted: September 10, 2018    Key Record Dates
Last Update Posted: February 11, 2019
Last Verified: February 2019

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Disease
Autistic Disorder
Autism Spectrum Disorder
Child Development Disorders, Pervasive
Pathologic Processes
Neurodevelopmental Disorders
Mental Disorders